US sales continued to progress with growth in the core aerospace and automotive markets.
- Established a regionalised manufacturer's representative network which is already showing signs of generating improved commercial traction within the North American steel mill, aerospace and automotive sectors for our finished tooling.
- As part of the commercial rollout, published full tooling parts catalogue and now building stock to support growth.
- We plan to drive further market penetration as additional distribution agreements are concluded.
- Added additional internal sales support with plans to reinforce technical support in Q2 FY24.
Consolidation in the UK of nanomaterial functionalisation technology offering leading to key partnership arrangements anticipated to form bedrock of continued commercial progress:
- continued to optimise and extend the functionality of the HDPlas® HT1400 plasma reactor installed in 2022:
- can functionalise nanomaterials for third parties on an industrial scale; and
- won an Engineering and Manufacturing Awards in September 2023 in the manufacturing technology innovation class.
- Signed commercial agreements with industry partners Saint Gobain, Cadent and Petronas:
- all have a commercial requirement that may potentially be met through the application of our plasma functionalisation process to their materials or the use of our wider product range; and
- can help take products to market through their market reach and capability.
- Working with several other nanomaterial producers and end customers where our HDPlas® process can bring additional value to their end customers.
- Secured financial support from the Welsh Government to continue the development of our key underfloor heating technology.
- Re-orientated our Thermal fluid technology to focus on Graphene by signing an agreement with an industry partner with expertise and market access.
- Revenue at £4.30 million (FY22: £2.90 million) up by 48.3% on prior year, driven predominantly by a continued recovery in the US business.
- Full year impact of the planned FY22 investment in sales, marketing, quality assurance and production capability saw adjusted administrative expenses increase by 12.5% to £6.26 million (FY22: £5.52 million).
- Adjusted operating loss increased slightly by £0.16 million to £3.49 million (FY22: £3.33 million).
- £5.1 million fundraising completed post period end.
Commenting on the results David Banks, Non-executive Chair of Haydale, said:
"We have made important progress in our next planned steps as a business by forging commercial partnerships and collaborations with leading organisations that the Board believe will ultimately help lead to commercial success. With the fundamental building blocks in place and continuing progress in our key markets, the Board remains confident that the Company will be able to take advantage of the traction it is now seeing."
I am pleased to present Haydale Graphene Industries Plc's full year audited results to 30 June 2023 ("FY23").
The Group continued to make positive progress during the year on its journey to delivering sustainable commercial revenues. The US operation in particular saw a strong bounce back in FY23 and, with its continued progress into the manufacture of SiC cutting tools, is increasingly well positioned to deliver strong growth moving forwards. The UK operation has started to see the seeds planted in FY22 begin to come through in the second half of FY23 and post year end period as we entered into a number of agreements that we believe will form the bedrock of strong business partnerships going forwards to take our offerings to the wider market. We anticipate the momentum across both the nanomaterial and SiC markets will continue into the current financial year.
Commercial revenue for FY23 of £4.30 million (FY22: £2.90 million) was up by 48.3% on prior year. Gross profit margin was slightly down due to sales mix at 56% (FY22: 60%) resulting in a gross profit of £2.39 million (FY22: £1.75 million). Other operating income for the year of £0.38 million (FY22: £0.44 million) was in line with last year after adjusting for US Covid support received in FY22. Adjusted administrative expenses increased by £0.74 million (12.5%) to £6.26 million (FY22: £5.52 million) primarily related to the full year impact of FY22 planned investment in resource resulting in an adjusted operating loss of £3.49 million (FY22: £3.33 million). Total administrative expenses were £8.93 million (FY22: £7.24 million) as a result of the above plus a number of additional non-trading items, namely increase in share-based payments charges of £0.55 million and an increase in depreciation and impairment of £0.40 million. Loss for the year was £6.17 million (FY22: £4.81 million).
The Group made good progress towards its longer-term goals in the year as the Company consolidated its position bringing increased focus onto its core offerings and laying the foundations for continuing growth in FY24 and beyond. The priorities of delivery of commercial revenue, focused investment in our physical and human capacity and development of our technology remains central to our strategy.
During the year we continued to optimise and extend the functionality of the HDPlas® HT1400 plasma reactor acquired in 2022 which allows us to manufacture functionalised nanomaterials on an industrial scale. With that assurance, we have further developed our collaborations with industry partners who, due to their market reach or capability, are potentially able to help take our products to market. We have also concluded commercial project arrangements with several nanomaterial producers and end customers where our HDPlas® process can bring additional value to their end customers.
The SiC and ceramic cutting tools produced by our US facility saw growth in their core aerospace and automotive markets. We started to roll out a regionalised manufacturer's representative strategy towards the end of FY23 which is already showing signs of generating improved commercial traction within the North American steel mill, aerospace and automotive sectors for our finished tooling. We anticipate this will increase further during the current financial year as additional distribution agreements are concluded.
I would like to thank our staff for their continued support and flexibility, as their efforts are key to us achieving our aims. I would also like to thank the executive management team who continue to drive the transition towards a sustainable commercial operation.
On 3 October 2023, the Company completed an equity funding of £5.1 million (gross) and I would like to welcome our new shareholders and to thank our existing shareholders for their continued support.
We have made important progress in our next planned steps as a business by forging commercial partnerships and collaborations with leading organisations that the Board believe will ultimately help lead to commercial success. With the fundamental building blocks in place and continuing progress in our key markets, the Board remains confident that the Company will be able to take advantage of the traction it is now seeing.
25 October 2023
FY23 has seen the Group's US operations continue its progress as demand returns for SiC powders and tooling in the aerospace and automotive industries. This has driven the overall FY23 revenue growth of the Group and looks set to help support the Group moving forwards with the expansion into the manufacture and sale of SiC tooling through a network of regional manufacturer representatives recently engaged across the USA. The UK based nanomaterial business has made significant steps in commercialising its portfolio of technology, especially in terms of business collaborations with significant industry players in key markets, having previously installed sufficient capacity to be able to process commercial levels of plasma functionalised nanomaterials for those partners and other third parties. These collaborations are expected to form a solid base to the expected progress in the current financial year.
The UK operations made significant progress over the year in progressing commercialisation of its proprietary technology which resulted in a number of key agreements being signed with industry partners in the last quarter of FY23 and first quarter of FY24. We anticipate these may lead to significant volume sales as those products and relationships mature over the next few years. Whilst progress on commercial arrangements has been strong, it is taking longer than expected for this to translate into revenue and, primarily due to one large functionalised product sale (goods) in FY22 not being repeated in FY23, total sales reduced by £0.20 million on prior year. Other consultancy revenues (services) grew by 11% on a like-for-like basis.
Patented Plasma Functionalisation Technology
At the core of all our product offerings and underpinning the Group's future nanomaterial prospects, is Haydale's patented HDPlas® plasma functionalisation process which improves the dispersibility of many nanomaterials by changing their surface chemistry using a highly tunable, repeatable process. Plasma functionalisation allows Haydale to tailor advanced materials to enhance the properties of its customers' products to achieve pre-agreed mechanical or conductive performance criteria. The process is cost effective and environmentally friendly and our capacity to produce industrial levels of functionalised nanomaterials underpins the business model. Specifically, we have the expertise to:
- functionalise nanomaterials that are blended with resins, composites and fluids to deliver enhanced electrical, mechanical (strength) and thermal performance;
- formulate proprietary nanomaterial-based inks and coatings for the print and sensor markets, including biomedical, RFID and piezo resistive inks and sensors; and
- compound functionalised nanomaterials into a range of elastomers to enable customers to use nanomaterials in elastomeric products.
The Group safeguards its nanomaterials business across its sites and the territories in which it operates through the use of patents and trade secret protocols which protect its intellectual property. It holds licences where that intellectual property is for operational reasons with a third party. Haydale currently has a portfolio of patents that are variously recognised in the following territories - US, UK, Europe, China, Japan and Australia. Haydale works closely with its patent advisors, Mewburn Ellis LLP, and maintains a rolling programme of patent applications.
Plasma Functionalised Powder Sales
We have secured a number of commercial contracts during the year with manufacturers of graphene to plasma functionalise their graphene powders to their requirements and are in discussions with many others who recognise the difference plasma functionalisation can make.
Of particular note, we have entered into contracts with a number of major industrial customers who manufacture their own nanomaterials. For Saint Gobain, who manufacture boron nitride, we are working with their end customers to hone the final surface chemistry to match their desired outcomes. Our ability to reliably adjust the surface chemistry has more recently led to our securing a major collaboration with Petronas to help them take their own graphene product, refined from a byproduct of their main petrochemical business, and functionalise it so it can potentially be recycled into other applications. We anticipate that all of these initiatives may lead to significant volumes needing to be plasma functionalised over the coming years, either directly by Haydale, or indirectly through the leasing of plasma reactors on a volume based royalty model.
Plasma Functionalised Products Sales:
Haydale has been working in the energy and heating sectors for a number of years. Geopolitical events and the UK Government's net zero strategy, have brought an increased urgency for solutions in this space.
Over the past few years, the Company has developed a number of off-the-shelf flexible heater graphene-based functional inks that can be printed onto a wide variety of surfaces. Based on those inks we are developing a range of low power heating products, potentially the most exciting of which is an energy efficient, cost-effective and easy to install underfloor heating system that could be used to supplement or replace domestic heating systems. The technology could be rolled out underneath the floor covering (e.g. carpet or tiles) and potentially run off a battery. With support from the Welsh Government, working prototypes have been created and are currently being tested in laboratory conditions to finalise the design before further optimisation and seeking a CE mark. We are now looking at various partnership options to take these to market.
We are also undertaking a number of paid projects for Cadent focused on helping energy suppliers meet their obligations to their vulnerable customers where they are under a legal requirement to be able to guarantee hot water and heating in situations where the power or gas go down. The initial project referred to last year involves a portable, battery powered water heater, a prototype of which is currently undergoing testing. We have also recently started work on a low power, portable over-the-radiator heating device which is also looking promising. Other potential applications of the same low power heating technology are currently in early-stage testing with partners.
In FY22 we announced we were working with a company that had acquired a patent for a boron nitride based thermal fluid. This has not progressed as we had hoped and is unlikely to lead to further revenues. We have however developed our own graphene based thermal fluid (patent pending) which early trials suggest performs with similarly positive thermal results and have now partnered with a specialist heating fluid engineering firm to finesse the formulation to work with the necessary additives so it meets applicable industry standards and can ultimately be deployed into their customer base.
Following on from the work historically undertaken in the biomedical ink sector, we have a range of off-the-shelf functional inks appropriate for use in biomedical and other sensor applications that can potentially detect a wide range of medical conditions. These inks have a high sensitivity and are therefore able to replace lower grade carbon inks and potentially metallic based inks in existing sensor products. Our work with a leader in the glucose monitoring and diabetes management sector is moving forwards following positive results against their existing inks and, having successfully passed an audit of the quality controls around production at our Ammanford site, we are now working with them on further tests. In the interim, we are separately working with a major European sensor manufacturer on an application to detect chlorine in water which we understand has a potentially lower barrier to entry, market wise.
Our collaboration with Vittoria Spa, a leading premium cycle tyre manufacturer, has progressed and, having proved the benefits that plasma functionalised graphene can bring to tyres (namely: grip, rolling resistance, puncture resistance and durability), we are shipping tonnage materials. We are also working with Vittoria on further enhancements for the next generation of tyres and anticipate the existing graphene enhancements to start trickling out to the wider market in due course.
In the second half of FY23, we released a graphene enhanced prepreg tooling material, following two years of trialling with Prodrive Composites Ltd, which is designed to deliver cost effective composite tooling with extended tooling life. This, and related products which were released during the year, are now seeing interest from the market which we hope will build through the current year.
Focused research and development
We continue to work on customer-paid and grant-funded projects to develop plasma functionalised nanomaterial solutions where there is a clear problem statement and we believe there to be a volume demand at the end of the process for any product created. We are selective and require a clear business case to proceed. By being able to deliver a number of selective projects that have resulted in a requirement for plasma functionalised material for third party applications or intellectual property that vests in Haydale, we have been able to build our underlying customer base. Key projects include the development of material that might be appropriate for type IV and V hydrogen storage tanks with Viritech for use in hydrogen powered vehicles and anti-counterfeiting technology using our PATit plasma functionalised graphene based conductive inks.
The performance of both the Thailand and Korea operations were at the lower end of expectation and, whilst we have been able to leverage our presence in these countries to secure several major clients for the Group as a whole including Petronas and Vittoria sourced by the Thailand office, it has been agreed that both entities are to be scaled back to a sales front office for the foreseeable future. This has been a progressive process which we will continue to monitor carefully. The Korea office concluded a beneficial commercial settlement with iCraft to terminate the agreement after they decided to focus on their core activities.
Silicon Carbide powders and tooling
Following prior year investment in the US and our move up the value chain into the manufacture of cutting tools, we have seen our silicon carbide and tooling business achieve significant growth in FY23. Although the raw SiC powder market is limited in scope (historically dependent on a small number of key customers) we continue to have additional sales in that area.
The SiC cutting tools is, by itself, a $900m market. Having previously invested in the necessary plant to manufacture our own SiC tooling and signed finishing service supply agreements to ensure we can meet capacity demands, towards the end of FY23 we released our first cutting tools catalogue and appointed four additional regional manufacturer representatives who act to introduce our product directly to end users on a commission only basis and thereby cost effectively extend our sales reach. The initial feedback we are receiving is very positive and we understand our tooling is exceeding the largest competitor in terms of durability and performance in a number of applications. This is starting to lead to a potential sizeable demand for product being reported by the manufacturer representatives which we anticipate will feed through into orders in the US hence we are taking steps to ensure inventory is available to support. We have recently secured an agreement with a distributor for the UK and Eire and are in discussions for similar arrangements in Asia. In addition, we have started acting as a seller of complementary non-SiC tooling in a number of areas and are also looking to develop further partnerships in this space through FY24.
There has been limited progress on CeramycGuard™, a one stop solution to significantly extend the surface life of concrete assets, for which Haydale holds the distribution rights for the UK market. Whilst accreditation with the Drinking Water Inspectorate ("DWI") has not been progressed due to the DWI not having the necessary capability at this time, we still believe that there remains a key market in the wider, non-drinking water market.
Haydale invested in production capacity for its plasma functionalisation process and ink production in FY22 and now has sufficient capacity to meet its forecasts for the next few years. Should additional capacity be required, Haydale has a scaling plan to affordably and materially increase its own internal capacity on relatively short timescales or, depending on client volumes, arrange for a machine to be leased to a client and charge a volume-based royalty.
Likewise, there is also more than sufficient capacity for the manufacture of SiC powder and tooling in the US to meet the business plan for the next few years.
The Directors continued to invest in the human capital across the wider business in FY23, strengthening the teams across UK and US operations and across the spectrum of sales, marketing, human resources, quality control and production. Whilst there will be further strategic hires required at the right time to manage the anticipated growth, there is not expected to be a need for any step change to deliver the business plan.
At the same time, the Group has also taken selective measures to reduce costs around the organisation. The scope of these is being extended as more focus is brought into the areas likely to lead to profit on a short-term basis.
FUTURE STRATEGIC DIRECTION
As noted above, the US operations have potential for strong growth in the short term through the manufacture and sale of specialised SiC tooling and complementary products. Having historically made the necessary capital investments, the focus is now on building the manufacturing representative network across the US and elsewhere to get the tooling into key end user sites.
Whilst Haydale has world leading technology for the functionalisation of nanomaterials, the focus for the UK is on building the business partnerships that will get its plasma functionalised nanomaterial solutions into the market and the organic growth that this will bring through repeat revenues at scale. This is concurrent to developing our own strategic products based on our existing solutions, such as underfloor heating, and we anticipate these, together with third party plasma functionalisation services, will form the basis of our future growth over the coming years in the UK.
The Directors remain mindful of the scaling challenges in both the US and UK that need to be managed for the Company to deliver the growth it expects to deliver as its early-stage industry partner relationships develop.
In the year under review, the Group's principal areas of income were sales of specialty inks, fluids and graphene enhanced composites and associated consultancy services from the UK and APAC operations and sale of SiC fibres, whiskers, particulate, blanks and tooling from the US operation. The Group's revenue for the year ended 30 June 2023 of £4.30 million (FY22: £2.90 million) represents a 48% increase compared with the previous year. Revenue derived from product sales increased by £1.33 million during the year, driven by the US business performance (See Note 3 - Segmentation Analysis).
The Group's Gross Profit, which excludes Other Operating Income, was £2.39 million (FY22: £1.75 million) delivering a Gross Profit margin of 56% (FY22: 60%) which is slightly down due to sales mix.
Other operating income, which is principally grant funded projects, was £0.38 million (FY22: £0.44 million) consistent with prior year after taking account of £0.06 million received in FY22 from US Covid Government Support packages.
Adjusted administrative expenses increased by £0.69 million (12.5%) to £6.26 million (FY22: £5.52 million) reflecting the full year impact of investment decisions taken in FY22 partially offset by cost savings resulting in an adjusted operating loss of £3.49 million (FY22: £3.33 million). Total administrative expenses for the year were £8.93 million (FY22: £7.24 million) which, in addition to the above, reflects additional non-cash related share-based payment expenses of £0.55 million. Also, the Group took the decision to impair the fixed assets held in the US and accordingly a non-cash charge of £0.53 million is included in total administrative expenses.
The Loss from Operations was £6.16 million (FY22: £5.06 million). Finance costs, which include interest payable on the Group's debt, for the year were £0.41 million (FY22: £0.19 million).
The Group continued to direct resources to research and development with the focus for that investment on products and processes that could develop into sustainable and profitable revenue streams. R&D spend for the year was £1.52 million (FY22: £1.45 million), of which £0.42 million was capitalized (FY22: £0.34 million). During the year the Group claimed R&D tax credits of £0.40 million (FY22: £0.43 million) and it is expected that this claim will be received during the current financial year.
Total comprehensive loss for the year, including £1.12 million (FY22: £0.41 million) of one off charges relating to impairment of tangible assets and share-based payment costs, was £5.80 million (FY22: £4.54 million).
The loss per share for the year was £0.01 loss (FY22: £0.01 loss).
Statement of Financial Position and Cashflows
As at 30 June 2023, net assets amounted to £6.97 million (2022: £7.05 million), including cash balances of £1.38 million (2022: £1.19 million). Other current assets marginally decreased to £3.15 million at the year-end (2022: £3.26 million) with modest reductions across most areas offset by an increase in inventory of £0.22 million at the US facility during the year. Current liabilities reduced slightly to £2.01 million (2022: £2.28 million) principally due to a reduction in trade and other payables.
The Right of Use Asset in respect of its leased premises decreased to £2.20 million (FY22: £2.70 million) due to winding down of the leases agreements. The Lease Liability which is split between Current and Non-Current Liabilities similarly decreased to £2.44 million (FY22: £2.92 million). These movements were non-cash items and did not impact the cash outflow in the year. The Company will amortise these balances over the remaining life of the leases which varies across the sites.
The Group's US Pension Obligations of £0.58 million (FY22: £1.36 million) has reduced in the year due to a combination of positive movements on investments, exchange and discount rate movements and contributions made.
Net cash outflow from operating activities before working capital movements for the year increased to £3.67 million (FY22: £3.42 million), the principal contributing factors being the Loss after Taxation of £6.17 million (FY22: £4.81 million). Cash used in Operations increased by £0.92 million in the year to £4.09 million (FY22: £3.17 million). The Group received an R&D tax credit inflow of £0.43 million in the year (FY22: £0.37 million). Net cash used in operating activities increased to £3.66 million (FY22 £2.80 million).
Capital expenditure in the year, excluding the IFRS 16 adjustments, was £0.20 million (FY22: £1.00 million).
Capital Structure and Funding
On 13 September 2022, the Company raised £5.51 million (gross) through the placing, open offer and subscription of 275,516,784 new Ordinary Shares at 2.00 pence per share. Consequently, at 30 June 2023 the Company had 785,852,475 ordinary shares in issue (2022: 510,335,691). No options were exercised into ordinary shares during the year (FY22: none).
The Group's total borrowings at the year-end were £1.37 million (2022: £1.35 million), of which £1.21 million was in the UK and the balance in the Group's US subsidiaries. The UKRI Innovation loan has a quarterly liquidity covenant until April 2024 with which the Group has been in full compliance through the reporting period. There are no financial covenants extant in respect of the UK bounceback loan of £0.03 million (FY22: £0.04 million) or the Group's US borrowings.
Post Balance Sheet Event
On 3 October 2023, the Company raised £5.1 million (gross) through a placing, retail offer and subscription of 1,012,609,000 new Ordinary Shares at 0.5 pence per share. The funds raised will be principally used to fund the general working capital needs of the business. As part of this process, the Company's share capital was restructured to in effect reduce the nominal value of each ordinary share from 2.0 pence to 0.1 pence.
Save for 576 shares issued following an exercise of warrants, all other warrants issued following the fundraise on 13 September 2022 of 138,758,392 lapsed on 14 September 2023 and are no longer exercisable.
Key Performance Indicators
The Group has historically reported financial metrics of revenues, gross profit margin, adjusted operating loss, cash position and other metrics as its key performance indicators and these are set out below.
Gross profit margin
Adjusted operating loss
During the year under review, management also used a sales tracker, a non-financial performance metric to monitor the revenue pipeline of the business. The sales tracker monitors the number of accredited leads and assigns a probability of revenue realisation to those leads.
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the year ended 30 June 2023
30 June 2023
30 June 2022
|Cost of sales||(1,911)||(1,156)|
|Other operating income||377||442|
|Adjusted administrative expenses||(6,260)||(5,520)|
|Adjusted operating loss||(3,493)||(3,333)|
|Adjusting administrative items:|
|Share based payment expense||(589)||(39)|
|Depreciation and amortisation||(1,552)||(1,308)|
|Total administrative expenses||(8,932)||(7,242)|
|LOSS FROM OPERATIONS||(6,165)||(5,055)|
|LOSS BEFORE TAXATION||4||(6,572)||(5,242)|
|LOSS FOR THE YEAR FROM CONTINUING OPERATIONS||(6,165)||(4,809)|
|Other comprehensive income:|
|Items that may be reclassified to profit or loss:|
|Exchange differences on translation of foreign operations||(341)||374|
|Items that will not be reclassified to profit or loss:|
|Remeasurements of defined benefit pension schemes||702||(109)|
|TOTAL COMPREHENSIVE LOSS FOR THE YEAR FROM CONTINUING OPERATIONS||(5,804)||(4,544)|
|Loss for the year attributable to:|
|Owners of the parent||(6,165)||(4,809)|
|Total comprehensive loss attributable to:|
|Owners of the parent||(5,804)||(4,544)|
|Loss per share attributable to owners of the Parent|
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 30 June 2023
|Company Registration No. 07228939||Note||30 June|
|Property, plant and equipment||5,915||7,579|
|Cash and bank balances||1,378||1,186|
|Trade and other payables||(1,899)||(2,199)|
|TOTAL NET ASSETS||6,972||7,048|
|Capital and reserves attributable to equity holders of the parent|
|Share premium account||31,912||31,912|
|Share-based payment reserve||833||244|
|Foreign exchange reserve||(353)||(12)|
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the year ended 30 June 2023
|At 30 June 2021||8,505||28,820||250||(386)||(30,430)||6,759|
|Comprehensive loss for the year|
|Loss for the year||-||-||-||-||(4,809)||(4,809)|
|Other comprehensive income/(loss)||-||-||-||374||(109)||265|
|Contributions by and distributions to owners|
|Recognition of share-based payments||-||-||39||-||-||39|
|Share based payment charges - lapsed options||-||-||(45)||-||45||-|
|Issue of ordinary share capital||1,702||3,401||-||-||-||5,103|
|Transaction costs in respect of share issues||-||(309)||-||-||-||(309)|
|At 30 June 2022||10,207||31,912||244||(12)||(35,303)||7,048|
|Comprehensive loss for the year|
|Loss for the year||-||-||-||-||(6,165)||(6,165)|
|Other comprehensive income/(loss)||-||-||-||(341)||702||361|
|Recognition of share-based payments||-||-||589||-||-||589|
|Issue of ordinary share capital||5,510||-||-||-||-||5,510|
|Share issue cost||-||-||-||-||(371)||(371)|
|At 30 June 2023||15,717||31,912||833||(353)||(41,137)||6,972|
CONSOLIDATED STATEMENT OF CASH FLOWS
For the year ended 30 June 2023
30 June 2023
30 June 022
|Cash flow from operating activities|
|Loss after taxation||(6,165)||(4,809)|
|Amortisation and impairment of intangible assets||335||607|
|Depreciation and impairment of property, plant and equipment||1,747||1,076|
|Profit on disposal of plant and equipment and F&F||-||8|
|Share-based payment charge||589||39|
|Pension: employer contribution||(180)||(92)|
|Operating cash flow before working capital changes||(3,674)||(3,416)|
|Increase in inventories||(218)||(187)|
|Decrease/(increase) in trade and other receivables||304||(4)|
|(Decrease)/increase in payables and deferred income||(503)||435|
|Cash used in operations||(4,091)||(3,172)|
|Income tax received||427||371|
|Net cash used in operating activities||(3,664)||(2,801)|
|Cash flow used in investing activities|
|Purchase of plant and equipment||(203)||(996)|
|Purchase of intangible assets||(421)||(340)|
|Net cash used in investing activities||(624)||(1,336)|
|Cash flow from financing activities|
|Finance costs - right of use asset||(116)||(125)|
|Payment of lease liability||(261)||(548)|
|Proceeds from issue of share capital||5,510||5,103|
|Share capital issues costs||(371)||(309)|
|New bank loans raised||-||454|
|Repayments of borrowings||(53)||(842)|
|Net cash flow from financing activities||4,500||3,670|
|Effects of exchange rates changes||(20)||9|
|Net increase/(decrease) in cash and cash equivalents||192||(458)|
|Cash and cash equivalents at beginning of the financial year||1,186||1,644|
|Cash and cash equivalents at end of the financial year||1,378||1,186|